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Introduction 
 
 
Pituitary adenylate cyclase activating polypeptide (PACAP) was isolated from ovine 
hypothalami in 1989. It was named after its effect on adenylate cyclase in the pituitary gland. 
PACAP occurs in two forms, with 38 and 27 amino acids. In mammalian species, PACAP38 is 
the dominant form, making 90% of PACAP. In the central nervous system, highest levels of 
PACAP can be shown in the hypothalamus, but other brain areas also contain PACAPergic 
neurons. It is well-known that PACAP is involved in the cellular protective machinery, both 
exogenous and endogenous PACAP has strong neuroprotective effects. The cytoprotective 
effects are mediated via a complex mechanism: it has antiapoptotic, antiinflammatory and 
antioxidant effects. About the detailed signaling mechanism, it is known that PACAP inhibits 
proapoptotic factors while stimulates antiapoptotic pathways. Its antiapoptotic effects have 
been described in several cell lines: PC12 cells, cholinergic neurons, dorsal root ganglionic cells 
and cerebral granule cells. Its in vitro protective effects have been shown against glutamate 
toxicity in retina neurons, against beta amyloid protein, 6-hydroxydopamine (6-OHDA), in 
vitro hypoxia and cell death induced by elevated calcium levels.  
The PACAP knockout mouse population used in our experiments shows early aging signs and 
increased sensitivity against stressors. A few biochemical mechanisms have been reported that 
can explain these phenomena, but little is known about detailed molecular mechanisms. The 
first step to obtain a closer insight is to perform qualitative and quantitative protein analysis and 
to determine changes in protein composition. Such analysis has not yet been performed in 
PACAP knockout mice. Thus, we have performed detailed proteomic analysis from samples of 
different brain areas of PACAP knockout mice. Experiments were done with gel-
electrophoresis based MALDI TOF/TOF high throughput system. Local distribution of proteins 
was also investigated in addition to the proteomic analysis. For this purpose, imaging mass 
spectrometry is a novel suitable technique. Due to the yet novel and not always standardized 
technique, results were confirmed with the well-known, routinely-used standardized LC-MS 
technology.  
Parkinson’s disease is a progressive, neurodegenerative disease, characterized by the death of 
the dopaminergic neurons in the substantia nigra pars compacta. The degenerated nigrostriatal 
pathway leads to the biochemical disturbance in this disease. Our research group has already 
investigated the protective effects of PACAP in vertebrate models of Parkinson’s disease. It has 
been shown that a pre-injury administration of PACAP into the substantia nigra protects 
approximately 50% of the dopminergic neurons in rats. Animals treated with PACAP perform 
significantly better in behavioral tests, they do not show hypoactivity symptoms and the 
improvement of the asymmetrical signs is significnatly faster than in the control group.  
Several models successfully reproduce several symptoms of the disease. The insecticide 
rotenone (a mitochondrial toxin) and the oxidative stress-inducing 6-OHDA are both able to 
induce experimental Parkinson’s disease. It has been shown that repeated rotenone treatment in 
invertebrates leads to some sympstoms similar to the vertebrate disease. Rotenone treatment 
causes decreased immunoreactivity in the giant dopaminergic neuron (RPeD1), which is the 
main dopamine-producing cell in the molluscan nervous system. This observation confirms that 
rotenone affects the dopaminergic system also in invertebrate disease models. The decrease of 
the dopamine levels in the central nervous system leads to progressive and irreversible decrease 
of apatite and motility, and also results in shorter life-span. The use of invertebrate models may 
be questioned, since the neuroanatomy of the invertebrate nervous system shows significant 
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differences from the vertebrate nervous system. However, at molecular and cellular levels 
several similarities also exist in vertebrate and invertebrate nervous systems, and the models 
also show similarities. The molluscan nervous system offers a unique opportunity to investigate 
cellular pharmacological processes, investigate biochemical mechanisms, basic behaviours and 
mechanisms of diseases.   
The decrease of dopamine levels correlate well with the degeneration of the dopaminergic 
neurons in the substantia nigra, mainly the decrease of this monoamine is in the background of 
the symptoms. Dopamine is one of the most widely distributed and most studied 
neurotransmitters of the central nervous system. Another very important transmitter is 
serotonin. In molluscs, in both the nervous system and the cardiac musculature, dopamine and 
serotonin are the monoamines with highest concentrations. Their concentrations range from a 
few micrograms to 30-40 micrograms/gram wet tissue. According to recent research data, 
serotoninergic transmission also seems to change in Parkinson’s disease. It is supposed that the 
subtypes of serotonin receptors also play a role in the manifestion of the disease.  
 
Aims 
- Our first aim is to perform proteomic analysis of PACAP knockout and PACAP wild-type 
mice with SDS PAGE-based MALDI TOF/TOF mass spectrometry.  
- Our aim was to determine PACAP-induced mechanisms linked to the differences in the protein 
composition.  
- A further aim was to compare localization of proteins in PACAP wild-type and PACAP 
deficient mice.  
- We aimed to determine whether PACAP-induced neuroprotective effects are conserved during 
evolution, therefore, as an invertebrate model, Lymnaea stagnalis, a molluscan species, was 
used. As a vertebrate model, we used Wistar rats.  
- We investigated whether PACAP has any effect on the dopamine and serotonin levels in the 
central nervous system. 
- We examined the changes in protein composition of the central nervous system upon induction 
of Parkinson’s disease. 
- Last, we investigated the effects of PACAP on dopamine metabolism. We determined the 
changes of the dopamine metabolizing enzymes (COMT, MAO-B) by Western blot in models 
using different mitochondrial toxins.  
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Materials and methods 
 
Brain proteomic analysis 
Wild-type (PACAP+/+, n=5) and homozygous PACAP-deficient mice (PACAP−/−, n=5) were 
used. Wild-type and homozygous PACAP-deficient mice were sacrificed under isoflurane 
anesthesia. Brains were removed and different brain areas (frontal cortex, temporal lobe–
diencephalon complex, mesencephalon, rest of the brainstem (pons and medulla), and 
cerebellum) were dissected. The tissue was homogenized, and cells were explored with a high 
energy UIS250V ultrasonicator.  Samples were vortex mixed and centrifuged at 10,000 rpm for 
10 min. Supernatant was transferred to new Eppendorf tubes, and 100 μl chloroformwas added. 
Using the chloroformed precipitation, a high grade of purity was reached; a high percentage of 
the presented lipids could be removed, which resulted in a good degree of ionization. The 
mixture was gently shaken for several seconds and then immersed into an ultrasonic water bath 
for precipitation 3 min. Phase separation was performed by a centrifugation immediately at 
4,000 rpm for 5 min. To get just the precipitated proteins, both the organic and the aqueous 
phases were removed.  
The instructions of the manual of Agilent 2200 TapeStation system were followed during the 
total sample preparation. The experiments and semiquantitative data analysis were carried out 
using the software of the 2200 TapeStation system. 
The brain samples from wild-type and PACAP-deficient mice were homogenized, (isoelectro 
focusing of the supernatant was performed with rehydrated IPG strips for the first dimension), 
SDS-polyacrylamide gel electrophoresis (PAGE) was carried out on 12 % polyacrylamide gel 
according to Laemmli. ProSieveTM QadColorTM protein marker, 4.6–300 kDa, was used for 
estimation of the molecular weight. Gels were stained with Coomassie Brilliant Blue R-250 
solution. The gels were analyzed by PharosFXTM scenner, Quantity One, PDQuestTM 2-D, 
BIO-RAD softwares. 
The bands of interest were excised from the gel with a razor blade, proteins were then reduced 
by dithiothreitol, and alkylated in iodoacetamide solution. The proteins were digested with 
modified trypsin. The tryptic peptides were lyophilized and to the identification was used by 
Autoflex Speed TOF/TOF mass spectrometer (Autoflex Speed-Bruker). To the resolved sample 
was added CHCA matrix solution.. The mass spectrometer operated in reflector mode for 
peptide mass fingerprinting (PMF) or LIFT mode for laser-induced decay (LID), and collision-
induced decay (CID) was used. The FlexControl 3.4 software was used to control the 
instrument. Singly charged monoisotopic peptide masses were searched against Swiss-Prot and 
NCBI databases by utilizing the MASCOT database search engine and Bruker ProteinScape 
server (Bruker Daltonics). Additionally, LID and CID fragmentation of three of the matched 
peptides were carried out with MALDI TOF/TOF to provide further evidence for the presence 
of the identified proteins. 
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Local brain protein distribution using IMS 
 
Wild-type (PACAP+/+, n=3) and homozygous PACAP knockout (PACAP-/-, n=3) mice were 
used in these experiments. Animals were perfused using physiological saline, in order to avoid 
the disturbing effects of blood remains for the mass spectrometry analysis. Twelve micrometer 
thick sections were made from the wild-type and knockout animals, which were placed on ITO 
(Indium-titan-oxide)-coated slides. The proper brain level was checked using Nissl staining. 
Cortex, hippocampus and hypothalamus were used for our samples. These slides were used for 
the determining of local protein changes.  
The lipids were removed with ethanol washing. The solvent residues were evaporated in 
vacuum. The dried slides were coated with CHCA (alpha-Cyano-4-hydroxycinnamic acid) 
matrix which promoted the molecular ionisation. A homemade automatic matrix sprayer system 
was used for the matrix coating. Autoflex Speed TOF/TOF mass spectrometer was used for the 
analysis. The mass spectrometer was operated in positive ion mode, the detection range was 
5000-25000 m/z. The FlexControl 3.4 Bruker Flex Imaging ClinPro Tools 3.1 softwares were 
used to control the instrument, data evaluation and statistical analysis. 
The proteomic results supported by nanoLC-MS method was based on one dimensional SDS 
PAGE. The samples were analyzed by nanoLC-MS method: nanoACQUITY ultra-performance 
liquid chromatography coupled to CaptiveSpray nanoESI Maxis 4G UHR-Q-TOF MS system. 
The samples were injected and separated on a 1.7 µm BEH130 C18 analytical column (75 µm 
x 100 mm). DDA fragmenting method was used for peptide sequencing in positive ion mode. 
The scanning mass to charge range was m/z 200-2200. Hystar 3.2, TrapControl 7.1, 
DataAnalysis 4.1 softwares were used for controlling the instrument, data acquisition and 
spectrum evaluations. The peptides were searched against Swiss-Prot and NCBI databases by 
utilizing the MASCOT database search engine and Bruker ProteinScape server. 
 
Parkinson’s disease model  
As an invertebrate model Lymnaea stagnalis, a molluscan species, was used. The animals were 
kept in containers filled with filtered Balaton water (18-20 °C), kept separately in groups. 
Animals not older than 3-4 months were used. These animals were considered as young 
animals. Snails were divided into 4 groups, each group with 40 animals. The first group was 
kept in filtered Balaton water, not injected with anything (control group). The second group had 
animals injected with 10 microgram PACAP38, and was kept in filtered Balaton water (PACAP 
group). The third group was injected with physiological saline and was kept in rotenone-
containing water (rotenone group). The fourth group was injected with PACAP38, and was kept 
in rotenone-containing water (rotenone+PACAP group). For the monoamine experiments, 32-
32 animals were used, which received treatments for 5 days (control, rotenone and 
rotenone+PACAP group).  
For the vertebrate experiments, Wistar rats were used. Animals (n=24) received 6-OHDA 
solution containing ascorbic acid into the substantia nigra. During the stereotaxic operation, 
animals were anesthetised with intraperitoneal pentobarbital. In the PACAP-treated group, 
animals received PACAP38 (n=11) before the 6-OHDA-induced lesion. PACAP was dissolved 
in physiological saline and was given with the help of Hamilton needle into the substantia nigra. 
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Control animals (n=4) received physiological saline under the same experimental 
circumstances.  
In the experiments with snails, the entire nervous system was prepared, while in rats, only the 
substantia nigra was removed. Dopamine and serotonin extraction was performed with a 
solution containing DTT and formic acid in acetonitril. Thereafter tissues have been 
homogenized and were explored with a high energy ultrasonicator. Samples were then vortex 
mixed and centrifuged. Then spinning supernatants were loaded in pure tubes and the solvents 
were evaporated with a SpeedVac concentrator at room temperature. The samples were 
dissolved fourfold volume of masses in ultra-pure water containing formic acid and loaded into 
autosampler vials for HPLC-MS measurements. 
Analyses were performed with a complex Ultimate 3000 micro HPLC system equipped with a 
quaternary pump, a degasser, and a QExactive UHR spectrometer. Separations were performed 
on a Kinetex PFP column (100 mm x 2.1 mm i.d., particle size 2.6 µm). A Q-Exactive orbitrap 
mass spectrometer equipped with a HESI source was used for mass detection. Xcalibur 2.2 
SP1.48 and Tune 2.1 softwares were used for controlling the instrument, data acquisition and 
spectrum evaluations. Filters of SIM and MS2 mode were used for selective and sensitive 
detection of DA and 5HT. The most intense precursor-to-fragment transitions were used for 
quantitative analysis such as, DA 154.08 → 137.06 m/z, 5HT 177.10→160.08 m/z. 
Statistics was performed with IBM SPSS Statistics- 20. version software. Normal distribution 
was confirmed with Kolmogorov-Smirnov test, deviation with Levene test. One way ANOVA 
with Scheffe and Tukey or Tamhane post hoc analysis was performed to investigate the 
significance.  
Western blot analysis was performed parallel in snail and rat samples. Three antibodies were 
used: anti-MAO B, anti-COMT and anti-actin as internal control. In snail samples, MAO-B 
enzyme could not be shown, therefore, we focused on COMT enzyme. Densitometric analysis 
was performed using Fiji Image J software.   
Proteomic analysis was used with nanoLC-MS method based on one dimensional SDS PAGE. 
nanoACQUITY ultra-performance liquid chromatography was coupled to CaptiveSpray 
nanoESI Amazon SL iontrap MS system. Proteomic differences were confirmed with ELISA 
measurements. PARK7/DJ-1 DuoSet ELISA Kit was used. Positive immunocomplexes were 
analysed with optic densitometry. The optical density reading was taken with a micro plate 
reader at 450, and corrected subtraction was used at 550nm for avoiding imperfections in the 
plate. 
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Results 
Investigation of protein composition 
The peptide–protein profile of the different brain regions (frontal cortex, temporal lobe–
diencephalon complex, mesencephalon, cerebellum, and the rest of the brainstem, which 
consisted of the pons and the medulla) of wild-type and PACAP-deficient mice was mapped on 
an Agilent 2200 TapeStation automated 1-D gel system. Frontal cortex and the rest of the 
brainstem (pons and medulla) regions of wild-type and PACAP-knockout mice did not show 
marked differences in protein composition. In contrast, significant differences were found in 
the mesencephalon and temporal lobe–diencephalon complex regions using Agilent 2200 
TapeStation system. We observed that several proteins (such as 50.8, 55.5, 61.1, 80.0, and 176.5 
kDa) were under level of detection in mesencephalon samples of PACAP-knockout (KO) mice. 
In contrast, a 12.9 kDa protein appeared in the same samples. Furthermore, the 14.9, 35.8, and 
52.8 kDa proteins were under level of detection in PACAP-knockout temporal lobe–
diencephalon complex region in contrast to wild-types. The main advantages of Agilent 2200 
TapeStation system are the simple sample preparation and the capability of quick measurements 
of a large number of samples, but its disadvantage is its limited resolution. Based on this, we 
were able to screen the different brain areas in a parallel fashion, but we could not reach a 
resolution that is high enough.  
Therefore, regions showing differences at first screening were further analyzed using SDS-
PAGE. The differences from mesencephalon and temporal lobe–diencephalon complex, a 
commonly used SDS-PAGE method was applied. The SDS PAGE could separate the different 
protein bands with higher resolution. In the most marked differences region, eight protein bands 
(∼39, 40, 45, 47, 50, 55, 60, and 70 kDa) with different intensity between mesencephalon in 
wild- and PACAP-knockout samples were identified. In the most obvious differences range, 
six protein bands (∼35, 36, 37, 40, 47, and 50 kDa) with different intensity between temporal 
lobe–diencephalon complex region in wild- and PACAP-knockout samples were identified. 
Since we could identify several proteins with MS analysis from the protein bands showing 
differences, 2-D electrophoresis was performed for more precise qualitative and quantitative 
analysis. 2-D electrophoresis enabled the separation of proteins over the entire pH 3–10 range 
and comprised proteins between 4.6 and 300 kDa. The spot abundance values were highly 
comparable among all wild-type and knockout samples. Spots showing marked differences 
between the two animal groups were excised and were further processed for MS analysis.  
We identified 22 proteins based on the sequences of the tryptic digests. In PACAP knockout 
mice, 14 proteins out of the 22 identified ones showed downregulation (peptidylprolyl 
isomerase A, glutathione S-transferase, malate dehydrogenase 1, enolase 2, aldolase 1, aspartate 
aminotransferase, leucine-rich repeat containing 9, phosphoglycerate mutase 1, pyruvate 
kinase, aconitase-2, hemoglobin subunit beta-1, albumin 1, histone (H1) domain, and secretin 
receptor), and in four proteins no difference was found (cytochrome c oxidase, glyceraldehyde- 
3-phosphate dehydrogenase, microphthalmia-associated transcription factor, and neurofascin). 
Four further proteins were identified that showed an upregulation in PACAP knockout mice 
(ATP synthase, tubb2 protein–tubulin beta-2 chain, spectrin alpha chain, and vinculin). 
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Local brain protein distribution using IMS 
 
Autoflex Speed MALDI TOF/TOF mass spectrometer was used for the imaging analysis. We 
applied 3-phase matrix coating to the homogenous matrix layer and a uniform tissue extraction.  
The first phase was the matrix spraying, the second was an incubation period. This phase is a 
very important period because this is when the proteins migrate from tissue to the matrix drops. 
The third phase was a drying period with pure nitrogen gas which minimalized the size of 
matrix-protein drop. We must avoid the drop-aggregation to the precise yield resolution. We 
tried more types of matrix, the CHCA matrix was the best for the protein analysis, so we used 
CHCA matrix in further experiments. The detection range was 5000-25000 m/z, parallel 
cryosections from PACAP knockout and wild-type brains were used. The Proper levels of 
sectioning were checked with Nissl staining and stereotactic atlas. 
Only minor morphological differences were observed, but differences were found in case of a 
few proteins. The most important difference found was the local distribution and quantity of 
beta-synuclein. The distribution of this protein is markedly more widespread in the wild-types 
than in the knockout samples. In order to prove the presence of this protein, protein extraction 
was performed from this brain level and gel-electrophoresis-based nanoLC-MS protein 
identification was performed from parallel samples. Protein identification resulted in 37 
proteins that could be identified with Mascot score≥80. Beta-synuclein (14043 Da molecular 
weight) was among them. This was well correlated with the molecular weight measured with 
IMS. The beta-synuclein was only confirmed in the samples derived from wild-type mice, while 
it was below limit of detection in the knockout samples. Another important protein is alpha-
synuclein with 14476 Da molecular weight, which could be identified in both samples. 
However, in the case of alpha-synuclein, the level was similar in the wild-type and knockout 
samples.  
 
Parkinson’s disease model  
Monoamine measurements  
For quantitative analysis of DA and 5HT five points calibration curves were made using 55.56; 
111.2; 556; 834; 1112 pmol/ml DA and 122; 305; 610; 1200; 2100 pmol/ml 5HT as standard. 
Correlation coefficients (r2) were between 0.9956 and 0.9989 for all acceptable calibration 
curves both in MS and MS/MS mode. The limit of detection was 2.9 pmol/ml and the limit of 
quantification was 5.8 pmol/ml for DA and 6.2 and 9.4 pmol/ml for 5HT, respectively. 
Monoamines were identified by their exact molecular weight and by their fragments according 
to literature data. Quantification of the data was made parallel both in MS and MS/MS mode. 
DA was identified at 154.09 m/z parent ion protonated form [M+H]+ and at 137.06 m/z 
fragment ion protonated form [F+H]+, which were characterized by 1.94 min retention time. 
The 5HT was identified at 177.10 m/z parent ion protonated form [M+H]+ and at 166.08 m/z 
fragment ion protonated form [F+H]+ which were characterized by 3.9 min retention time. 
These data confirm those described earlier.  Based on these data identification of monoamines 
both in invertebrate and vertebrate samples was performed. 
Invertebrate model – Lymnaea stagnalis 
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The neuroprotective effects of PACAP were investigated in rotenone-induced invertebrate 
model of Parkinson’s disease. Snails were treated with 0.5 microM rotenone. One group 
received 10 microgramm PACAP38 dissolved in 100 microliter physiological saline. The 
treatment lasted 12 days. The number of snails surviving the treatment was 10 and 9 in the 
control and PACAP-injected groups, respectively. Snails injected with saline and kept in 
rotenone-containing water started to die on day 5 and all snails were dead by day 12. Although 
PACAP-injected snails kept in rotenone-containing water started to die earlier (days 3 and 4), 
markedly more animals survived till day 12. This means that 50% of this group stayed alive till 
the end of the experiment.  
In the next experiments, average monoamine concentrations were determined in the whole 
central nervous systems on control animals using HPLC-MS system. For dopamine it was  
3.33±0.76 µg/g tissue and for serotonin it was  9.87±1.87 µg/g tissue. In the rotenone group, 
dopamine levels decreased by 44.7±12.15 % (n=28). In contrast, in the rotenone+PACAP 
group, the decrease was significantly smaller: (26.5±11.5 %, n=30), which confirms a 
neuroprotective effect. However, serotonin levels showed a further decrease in the 
rontenone+PACAP group compared to the rotenone group. In the rotenone group, serotonin 
levels were decreased by 35.5±9.70 %, while in PACAP-injected group this decrease was 
49.9±8.60 % (n=30). Seemingly, PACAP influences dopamine and serotonin levels in reverse 
directions in the snail nervous system.  
We investigated the metabolizing enzyme (COMT) in control, rotenone and rotenone+PACAP 
groups using Western blot. The other important monoamine metabolizing enzyme, MAO B was 
also investigated, but its presence could not be confirmed in the snail. It is well known from the 
literature that this enzyme may not be found in invertebrates, although controversies also exist. 
The accepted novel view is that even if the enzyme is present, it plays a very little role in the 
metabolism in invertebrates. Since we could not identify this enzyme either, in further 
experiments we focused on the COMT enzyme. As an internal control, anti-actin antiserum was 
used in the samples (40 kDa). The COMT enzyme level proved to show treatment-dependent 
changes (rotenone and rotenone+PACAP). Positive immunoreactive bands were observed at 23 
and 26 kDa, which correlates well with the data given by the manufacturer. The 23 kDa peak 
represents soluble COMT enzyme (S-COMT), while the 26 kDa peak represents the membrane-
bound COMT enzyme (MB-COMT). The densitometric analysis showed significant 
differences in the S-COMT, which showed higher levels in the control group compared to the 
rotenone and rotenone+PACAP groups (normal distribution, t-test p<0.001). The membrane-
bound COMT enzyme shows higher levels in the rotenone- group compared to both the control 
and the rotenone+PACAP groups (normal distribution, t-test p<0.001). These data confirm the 
effects of rotenone in dopamine metabolism.     
Vertebrate model – rat 
As a first step, we investigated the time-dependence of dopamine deficiency using the toxin 6-
OHDA. Brains were processed for analysis 1, 3, 7, 9, 12, 14 and 16 days after the operation. 
Substantia nigra was immediately removed and LC-MS examination determined the dopamine 
concentration. Due to the characteristics of the toxin and type of lesion (unilateral), we had 
control samples from the same animals as well (right side). The left side dopamine 
concentration was compared with that of the right side. The drastic (~ 50 %) drop of dopamine 
levels was observed on day 7 after the operation. It was only 10% on days 1-2 and no further 
changes were observed between days 7 and 16. Therefore, 7 days after the operation, we 
considered the dopamine level decrease as final, characteristic in Parkinson’s disease. For this 
reason, in further experiments, animals were investigated 7 days after the injury. We performed 
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monoamine analysis in the substantia nigra in control animals: dopamine was 4.24±0.7 µg/g 
tissue (n=4), serotonin was 3.53±0.45 µg/g (n=4) tissue. 6-OHDA injected group had decreased 
(to 51.3±4.65 %) dopamine levels (n=6), while significantly smaller decrease was observed 
(26.1±4.31 %, n=7) in the PACAP-treated animals. Serotonin content of the subsantia nigra of 
the 6-OHDA-injected group was decreased to 40.4±4.77 %, while 6-OHDA + PACAP-treated 
groups showed a decrease to 57.6±9.70 % (n=7). These data suggest that PACAP compensates 
dopamine deficiency in a model of Parkinson’s disease, and it influences monoamine levels 
similarly in invertebrate and vertebrate organisms.  
The two enzymes important in dopamine metabolism were also analysed by Western blot. As 
an internal control, anti-actin antiserum was used in the samples (40 kDa).  In case of COMT, 
positive immunoreactive bands were observed at 23 and 26 kDa, which correlates well with the 
data given by the manufacturer. Similarly to the invertebrate model, the COMT enzyme level 
proved to show treatment-dependent changes (6-OHDA and 6-OHDA+PACAP). The 
densitometric analysis showed significant differences in the S-COMT, which showed higher 
levels in the control group compared to the 6-OHDA and 6-OHDA+PACAP groups (normal 
distribution, t-test p<0.001). The membrane-bound COMT enzyme shows higher levels in the 
6-OHDA group compared to both the control and the 6-OHDA+PACAP groups (normal 
distribution, t-test p<0.001). These data confirm the effects of 6-OHDA in dopamine 
metabolism. In case of MAO-B, immunopositive band was observed at 55 kDa, no significant 
difference was between the groups. 
Proteomic analysis was performed in Parkinson’s disease models. One-dimensional SDS-
PAGE electrophoresis was performed from the substantia nigra homogenates, repeated 3 times 
on each experimental day. The densitometric analysis revealed no major changes in the protein 
composition between any groups.   
In order to map the protein composition and to reveal smaller differences, nanoLC-MS 
measurements were performed. Significant number of proteins were analysed using protein 
database (95 proteins), with one major difference between the groups. The SDS-PAGE based 
nano-LCMS measurement revealed a difference in PARK7/DJ-1 protein, but the protein was at 
a level close to the limit of detection. Therefore, in order to determine exact differences, we 
performed snadwich ELISA measurements, in samples from both snails and rats. Both toxins 
(6-OHDA and rotenone), led to a significant decrease of this protein. PACAP was able to 
counteract this decreasing effect in the vertebrate, bot not in the invertebrate, model.  
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Discussion 
Brain protein composition 
Our study revealed several proteins that were up- or downregulated in intact mice lacking 
endogenous PACAP. This is the first mass spectrometric analysis of PACAP-knockout mice 
using MS and Agilent 1-Dimension Automated 2200 TapeStation system. Based on our current 
knowledge on mice lacking endogenous PACAP, it seems that there are no visible differences 
or only minor alterations are present in the brain morphology of PACAP-KO mice at 
macroscopic or light microscopic levels. However, when these mice are exposed to harmful 
challenges, including hypoxia/ischemia, trauma, and toxicity, PACAP-knockout mice respond 
with a significantly increased lesion. This has been proven in models of experimental 
autoimmune encephalomyelitis, brain ischemia, retinal ischemia, and retinal excitotoxicity. 
Furthermore, mice lacking endogenous PACAP have shown slower regeneration in spinal cord 
and peripheral nerve injury. These results suggest that there must be biochemical alterations 
that can be compensated under unchallenged conditions in the absence of PACAP, but the 
compensatory mechanisms are not sufficient to overcome injuries and to provide cellular 
protection under challenged conditions. Our present results may shed further light on the 
increased vulnerability of PACAP-deficient mice against different challenges. 
One group of proteins, where marked differences were found, was proteins related to oxidative 
stress and antioxidant defense. These proteins were found to be downregulated in PACAP-
knockout mice. Peptidylprolyl isomerase A(PPIase), for example, plays a key role in heat shock 
protein-induced stress response. Glutathione S-transferase is important in detoxification and 
antioxidant defense. These results are in accordance with earlier observations showing that 
PACAP knockout mice have increased oxidative stress levels, with increased 
malonedialdehyde, decreased glutathione, and decreased superoxide dismutase. Furthermore, 
while no differences have been found in the antioxidant capacity and reactive oxygen species 
levels in the serum of knockout and wild-type mice at young ages, decreased antioxidant 
capacity accompanied by increased reactive oxygen species levels at older knockout mice has 
been found. A recent study has investigated the PACAP-induced changes after cerebral 
ischemia in mice. The authors have found upregulation of antioxidant defense molecules after 
PACAP administration. In addition, an earlier study in PC12 cells found increased protective 
heat shock protein 27 levels while decreased neurotoxic heat shock protein expression after 
PACAP treatment. All these results, in accordance with our present data, point to the 
importance of both endogenous and exogenous PACAP in protection against oxidative stress. 
Another group of proteins, where we found major differences between the two groups, was the 
group of glycosylation enzymes. Malate dehydrogenase 1, enolase 2, aldolase 1, 
phosphoglycerate mutase 1 (PGM), and pyruvate kinase (PK) were downregulated, while ATP 
synthase was upregulated. Similarly to the oxidative stress markers, the changes in glycolytic 
enzymes in the present study are also in accordance with the findings of Hori et al. (2012) 
showing that exogenous PACAP influences the enzymes participating in glycosylation are 
altered after PACAP treatment in favor of a positive energy balance, supposedly providing 
protection in ischemic lesions. These results and our present observations suggest that 
endogenous PACAP is necessary for providing a favorable energy balance. In the lack of this 
regulatory mechanism, this energy balance is disturbed, making the organism more vulnerable 
to noxious stimuli (hypoxia, ischemia, aging, toxins, and neurodegenerative conditions). These 
results are also in accordance with studies showing that stimulating this enzymatic machinery 
provides neuroprotection in hypoxia. Our results also show that PACAP-knockout mice might 
compensate this disturbed energy balance by increasing ATP synthase levels under intact or 
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unstressed conditions. This is in accordance with the observations of Ohtaki et al. (2010) 
showing that young knockout mice do not have increased oxidative stress in contrast to aging 
mice. We found several other differences in protein composition, including structural proteins, 
the functional significance of which is under further investigation. It is well-known that results 
obtained from knockout mice have to be handled carefully and no direct functional 
consequences can be drawn regarding the exact endogenous actions of the molecule. The 
compensatory mechanisms in case of PACAP-knockout mice are not fully understood. Several 
attempts have been made to elucidate the compensatory changes in the lack of PACAP. 
However, the first studies found no differences in the monoaminergic neurotransmitter systems. 
Subsequent experiments hypothesized that there could be compensation by vasoactive intestinal 
peptide (VIP), the peptide with the closest structural homology to PACAP. In spite of this 
theoretical possibility, no compensatory changes were found in the expression of VIP in the 
brain. Therefore, it is still not known what mechanisms compensate the endogenous lack of 
PACAP, and it is possible that indirect compensatory effects exist, like the here-described 
differences in the proteins playing a role in the energy balance. 
These results open a novel direction to investigate alterations in PACAP-deficient mice that 
may explain their increased vulnerability to different harmful stimuli affecting the nervous 
system. Based on our present results, it seems that endogenous PACAP affects energy 
homeostasis and in lack of this neuropeptide, a disturbed energy balance exists which cannot 
be compensated in case of an environmental challenge. 
 
 
 
Local brain protein distribution using IMS 
Spatial distribution of proteins provides additional information about biological mechanisms. 
Imaging mass spectrometry is a novel, still developing  technique, which provides 
measurements without labelling. However, due to the methodological limitations, it can be used 
only after careful consideration. As an additional technique, we need to use structure 
identification and confirmation. For this purpose, we used nanoLC-MS measurements.  
Our measurements confirmed that PACAP knockout mice had decreased levels of beta-
synuclein, while alpha-synuclein was present at the same concentration on both populations. 
Maroteaux and coworkers published the first results on the significance and biological roles of 
the synuclein protein family in 1988. Alpha- and beta-synuclein have been described in the 
cortex, hippocampus, thalamus and cerebellum, on the presynaptic sides of neurons. Since then, 
their role has been described in several neurodegenerative disorders, among them, in 
Alzheimer’s and Parkinson’s diseases. Lewy bodies play an important role in the disease 
pathology and progression of Parkinson’s disease. These Lewy bodies are abnormal protein 
aggregates of apha-synuclein. Beta-synuclein plays a role in the inhibition of the alpha-
synuclein aggregates, playing a neuroprotective role. Several aspects of the mechanism of 
action have also been reported in recent papers, described in models of neurodegeneration 
induced by rotenone and 6-OHDA. Akt signaling has been observed to show increased activity 
due to the direct connection between beta-synuclein and Akt. These observations explain well 
the observed neuroprotective effect. The above examples support that in case of PACAP 
deficiency, beta-synuclein is decreased and therefore, important protective pathways may be 
lesioned. This can lead to an increased risk for the occurrence of neurodegenerative diseases.  
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Our results further support the neuroprotective efficacy of PACAP in Parkinson’s disease, 
therefore, we continued our experiments with investigating the role of PACAP in this disease. 
In this model, we investigated PACAP knockout mice and observed that the symptoms are more 
severe in PACAP deficient animals than in wild-types. However, we have faced difficulties in 
examining the behavioral symptoms, and that is the reason why we used a rat model for further 
experiments.  
 
Parkinson’s disease model  
As a first step, we investigated the time-dependence of dopamine deficiency using the toxin 6-
OHDA. The drastic (~ 50 %) drop of dopamine levels was observed on days 3-7 after the 
operation. Therefore, 7 days after the operation, we considered the dopamine level decrease as 
final, characteristic in Parkinson’s disease. For this reason, in the further experiments, animals 
were investigated 7 days after the injury, which correlates well with data known from the 
literature. We observed that in both the 6-OHDA and in the rotenone models, dopamine and 
serotonin levels were significantly decreased compared to the controls. In groups receiving 
PACAP treatment, PACAP could counteract the toxin-induced decrease in the dopamine levels, 
as it inhibited the drastic decrease in this monoamine level in both models. This observation 
can explain that some characteristic behavioral symptoms (hypokinesia) could not be observed 
earlier in a rat model of Parkinson’s disease after PACAP treatment, or they showed an earlier 
recovery than in control rats. These additional data are important in understanding the behavior-
improving effect of PACAP in Parkinson’s disease, since the inhibition of the drastic dopamine 
level decrease can ameliorate the severe clinical symptoms in addition to the ameliorating effect 
on chronic symptoms as well. Furthermore, PACAP treated animals show decreased 
dopaminergic cell loss. Thus, our results are in accordance with previous observations, 
completes them, and provide further additional data in order to understand the mechanism of 
action exerted by PACAP in neurodegenerative diseases.  
Examining the brain serotonin concentrations, we did not observe such PACAP effect as with 
the dopamine measurements. At the moment, we do not know the background reason for this 
difference. In Parkinson’s disease, some studies have shown decreased serotonin levels, while 
others increased levels, so no firm conclusions can be drawn from data obtained so far. One of 
the deleterious effects of alpha-synuclein in Parkinson’s disease is that it forms an aggregate 
with the neurotransmitters dopamine and serotonin, thus further decreasing the already 
decreased levels of these transmitters. Based on the effects of PACAP on dopamine, we 
expected that it would also counteract the effects of the lesion on serotonin levels. However, 
LC-MS measurements showed that this mechanism might not be present. We suppose that the 
mechanisms described earlier can explain the decrease in serotonin levels, according to which 
serotonin plays a role in the release of dopamine, therefore, decreased serotonin levels might 
compensate in the disturbed dopamine balance.  
We investigated the metabolizing enzyme (COMT) in control, rotenone and rotenone+PACAP 
groups using Western blot. The other important monoamine metabolizing enzyme, MAO B was 
also investigated, but its presence could not be confirmed in the snail. It is well known from the 
literature that this enzyme may not be found, although controversies also exist. The accepted 
novel view is that even if the enzyme is present, it plays a very little role in the metabolism. 
Since we could not identify this enzyme either, in the further experiments we focused on the 
COMT enzyme. 
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The metabolic enzyme occurring in both species, COMT, showed similar changes in both 
vertebrate and invertebrate models. We observed a significant decrease in S-COMT in both the 
6-OHDA and rotenone models, which could not be antagonized by PACAP treatment. 
However, MB-COMT levels significantly increased due to the toxic treatments and this effect 
could be reversed by PACAP treatment. We suggest that the increased level of MB-COMT was 
an additional effect in decrease in dopamine levels in the toxin groups. There are important 
differences in the functions of the two forms of the enzyme. The primary function of the MB-
COMT is the inhibition of dopaminergic neurotransmission. Since the most important regulator 
of dopamine in the brain is the COMT enzyme and it is closely related to behavioral and 
cognitive functions, we suggest that the decrease observed both in the 6-OHDA and the 
rotenone models have an additional impact on the decreased dopaminergic neurotransmission.  
In the invertebrate model we observed that the mortality of PACAP-treated animals did not 
differ from control animals. Animals receiving only rotenone all died by the 12th day, while 
50% of snails receiving rotenone and PACAP treatment stayed alive. This observation supports 
the neuroprotective effect of PACAP in models of neurodegenerative diseases. In addition, we 
observed that more rotenone+PACAP-treated animals died between days 3-8 than the rotenone-
treated animals. We suggest that rotenone+PACAP treatment induces a chronic (less degree) 
stress reaction, which is present from the beginning of the experiment, accounting for the 
continuous loss of animals. In contrast, rotenone-treatment induces an acute, stronger response, 
calling for acute compensatory mechanisms that wear out by the 8th day and after that rotenone 
induces a higher degree of stress. That may be the reason for the increased mortality in these 
animals.  
Significant number of proteins were analysed using a protein database (95 proteins), with one 
major difference between the groups, it was the PARK7/DJ-1 protein. PARK7/DJ-1 protein is 
a member of the C56 peptidase family, it is a positive regulator of androgen-dependent 
transcription. It belongs to the redox sensitive chaperon proteins, and it has a role in sensing 
oxidative stress. Earlier studies have suggested three potential mechanisms, through which DJ1 
protein exerts neuroprotective effects. DJ1 protein stabilizes NRF2 protein, which is a 
transcription  factor and is a main regulator of the cellular antioxidant protective system. As 
such, it inhibits oxidative stress-induced cell death, and therefore, it may prevent 
occurrence/progression of Parkinson’s disease. DJ1 protein inhibits protein associated splicing 
factor (PSF), which has a transcription silencing effect under normal circumstances, thus 
increases neuronal apoptosis. It inhibits mutant alpha-synuclein aggregation, thereby prevents 
Lewy body formation important in the pathogenesis of Parkinson’s disease.  
Our ELISA measurements showed decreased concentrations of PARK7/DJ-1 protein in the 6-
OHDA and rotenone-treated groups compared to the control ones. In the vertebrate model, 
PARK7/DJ-1 protein level was similar to the control group in the PACAP-treated groups, but 
we did not observe this protective effect in the invertebrate model. We suppose that the lack of 
the protective effect may be due to the differences in the applied toxins or the activation of 
different signaling pathways.   
In summary we conclude that the neuroprotective effect of PACAP in models of 
neurodegeneration is correlates well with the changes in the monoamine neurotransmitters. We 
suggest that PACAP initiates evolutionarily conserved molecular and cellular mechanisms, 
which induce neuroprotection. The monoamine neurotransmitters and the metabolizing 
enzymes undergo similar changes in the vertebrate and invertebrate models, but this was not 
observed in the protein PARK7/DJ-1. We confirmed that the PACAP- PARK7/DJ-1 protein 
signaling is only present in vertebrates. We also confirmed that the invertebrate rotenone-model 
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of Parkinson’s disease well mimics some symptoms of the vertebrate disease and offers an 
alternative model to study the protective effects of PACAP.  
 
Conclusions, novel findings 
- We compared the protein composition of PACAP deficient and wild-type mice.  
- We identified some changes in protein expression that can, at least in part, provide the 
background for the increased vulnerability and enhanced aging in PACAP knockout mice. 
Among them, glycolitic enzymes, antioxidant enzymes and proteins which playing a role 
against oxidative stress. We identified some supposedly compensatory mechanisms, like 
increased ATP synthase levels.  
- We confirmed decreased level of beta-synuclein in PACAP knockout mice using MALDI 
IMS technique and we summarized the protective effects of PACAP-beta-synuclein.  
- We confirmed that the rotenone-induced neurodegeneration model used in invertebrates is a 
suitable model to study monoamine and enzyme changes as well as molecular biological 
measurements, similarly to the vertebrate 6-OHDA model.  
- We confirmed the previously demonstrated neuroprotective role of PACAP in models of 
neurogeneration correlates well with the changes in the neurotransmitters.  
- We examined the quantitative changes in the dopamine metabolizing enzymes and we 
confirmed that the MAO-B enzyme is not present in Lymnaea stagnalis, thus it cannot play a 
significant role in the dopamine metabolism.  
- We have performed proteomic analysis in the vertebrate model and confirmed marked 
quantitative difference only in DJ1 protein.  
- We examined, for the first time, the connection between PACAP and PARK7/DJ-1. We 
confirmed the exact quantitative changes of this protein in our models using sandwich ELISA. 
We confirmed, for the first time, the presence of PARK7/DJ-1 protein in Lymnaea stagnalis.  
-  We  provided a possible explanation for the changes of serotonin levels, according to which 
serotonin plays a role in dopamine release, therefore, decrease in serotonin levels can be a 
compensatory mechanism.  
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